Expectations about CC on Tuesday

The last interview was "hastily arranged" and had no heads or tails apart from the fact that, likely, was made it as to convey the fact that the commercialization deal had been put on hold.

The Oncology potential was put forward as an explanation. As Fortuno has proposed, this might me a good reason (pricing in Oncology is grater than pricing in HIV and, once this is set for HIV it would be difficult to increase it for cancer indications).

However, and understandably, Nader I am sure, is receiving a deluge of mail and, I believe the CC is in part to explain what happened (and what is happening) with the commercialization deal we all where waiting for.

Few possibilities:

1) The deal has been put on hold becase there is no agreement between the parts. After negotiations either us, or our potential partners, decided that it was not good enough and decided to terminate the talks.

2) The deal was concluded at mutual accord, but, being non-binding, CYDY (or our partner) requested more time to decide and sign it at a latter time if convenient for either company.

3) Something new has come up that changed the landscape: an offer in other indication (NASH, PrEP ...) , another offer in HIV, or another country, a good possibility with new data, news from FDA delaying something, etc. One, or both parties have decided to wait until things clarify.

Only one thing is certain: we do not have a deal for the time being and the financial future is uncertain at the moment. The CC will be a good opportunity to learn what lies ahead.

Also, I am sure NP will update us in BLA filing status vis-a-vis FDA decision on dosage (if any).

Lets hope we have good news in general to take home for Christmas.